MX2022013236A - Tratamiento de la obesidad hipotalamica. - Google Patents

Tratamiento de la obesidad hipotalamica.

Info

Publication number
MX2022013236A
MX2022013236A MX2022013236A MX2022013236A MX2022013236A MX 2022013236 A MX2022013236 A MX 2022013236A MX 2022013236 A MX2022013236 A MX 2022013236A MX 2022013236 A MX2022013236 A MX 2022013236A MX 2022013236 A MX2022013236 A MX 2022013236A
Authority
MX
Mexico
Prior art keywords
treatment
hypothalamic obesity
disclosure relates
hypothalamic
obesity
Prior art date
Application number
MX2022013236A
Other languages
English (en)
Inventor
Jørgen Drejer
Kim Krogsgaard
Berit Edsberg
Original Assignee
Saniona As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saniona As filed Critical Saniona As
Publication of MX2022013236A publication Critical patent/MX2022013236A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Abstract

La presente descripción se relaciona con el tratamiento de la Obesidad Hipotalámica con Tesofensina sola o en combinación con un bloqueador beta. En particular la descripción se relaciona con tratamientos que conducen a la pérdida de peso, pérdida de masa grasa, en particular grasa visceral y la reducción de síntomas de la prediabetes en pacientes que padecen de Obesidad Hipotalámica.
MX2022013236A 2020-04-22 2021-04-22 Tratamiento de la obesidad hipotalamica. MX2022013236A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20170952 2020-04-22
EP20209186 2020-11-23
PCT/EP2021/060548 WO2021214233A1 (en) 2020-04-22 2021-04-22 Treatment of hypothalamic obesity

Publications (1)

Publication Number Publication Date
MX2022013236A true MX2022013236A (es) 2023-01-24

Family

ID=75562770

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022013236A MX2022013236A (es) 2020-04-22 2021-04-22 Tratamiento de la obesidad hipotalamica.

Country Status (5)

Country Link
EP (1) EP4138830A1 (es)
JP (1) JP2023523738A (es)
CA (1) CA3176183A1 (es)
MX (1) MX2022013236A (es)
WO (1) WO2021214233A1 (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL185132B1 (pl) 1996-02-22 2003-02-28 Neurosearch As Pochodne tropanowe, ich wytwarzanie i zastosowanie, oraz zawierająca je kompozycja farmaceutyczna
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
AU2003282375A1 (en) 2003-02-05 2004-08-30 Ipca Laboratories Limited Pharmaceutical compositions and process of production thereof
DE102005034351A1 (de) 2005-07-22 2007-01-25 Sension, Biologische Detektions- Und Schnelltestsysteme Gmbh Farb-Umschlag-Indikator zur Statusanzeige von RFID-Tickets und -Etiketten
US20070053983A1 (en) 2005-09-06 2007-03-08 Girish Jain Extended release compositions of metoprolol succinate
US20070092573A1 (en) 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
US8815285B2 (en) 2006-03-28 2014-08-26 Wockhardt Ltd. Extended release dosage forms of metoprolol
US20090324717A1 (en) 2006-07-28 2009-12-31 Farmaprojects, S. A. Extended release pharmaceutical formulation of metoprolol and process for its preparation
US8235632B2 (en) 2010-05-14 2012-08-07 Illinois Tool Works Inc. Cargo bag valve deflector
WO2012052834A2 (en) 2010-10-21 2012-04-26 Inventia Healthcare Private Limited Multiple unit particulate system comprising metoprolol succinate
WO2013030725A1 (en) 2011-08-26 2013-03-07 Wockhardt Limited Methods for treating cardiovascular disorders
CA2858522A1 (en) 2011-12-09 2013-06-13 Wockhardt Limited Methods for treating cardiovascular disorder
JP6203760B2 (ja) 2012-02-16 2017-09-27 サニオナ・エー／エス 併用療法のための医薬組成物
WO2015004617A1 (en) 2013-07-09 2015-01-15 Ranbaxy Laboratories Limited Extended-release pharmaceutical compositions of metoprolol
EA033298B1 (ru) 2015-03-03 2019-09-30 Саниона А/С Комбинированная лекарственная форма тезофензина и метопролола
MX2021008208A (es) * 2019-01-07 2021-11-17 Saniona As Tesofensina para la reduccion del peso corporal para pacientes con sindrome de prader-willi.

Also Published As

Publication number Publication date
EP4138830A1 (en) 2023-03-01
JP2023523738A (ja) 2023-06-07
CA3176183A1 (en) 2021-10-28
WO2021214233A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
EA033415B1 (ru) Способы лечения ожирения, применение ингибитора dpp-4 в этих способах и способ лечения пациентов, страдающих диабетом типа 2
WO2020047462A3 (en) Methods of treating aging-related disorders
MY188365A (en) Diagnosis and treatments relating to th2 inhibition
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
MX2020009911A (es) Usos de inhibiores de dpp iv.
WO2007130882A3 (en) Method for treatment of diarrhea-predominant irritable bowel syndrome
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
IL208992A (en) Use of h2 relaxin active pharmacist in the manufacture of drugs for the treatment of shortness of breath related to acute heart failure and decompensatory acute heart failure
MX2018008709A (es) Uso terapeutico de inhibidores de activacion o estimulacion de celulas t.
MX338447B (es) Tratamiento para diabetes en pacientes inapropirados para terapia con metformina.
WO2011020061A3 (en) Compositions and methods of for treating bipolar disorder
MX348184B (es) Métodos y composiciones para tratar diarrea asociada con vih.
MY165160A (en) TREATMENT OF MYOCARDIAL INFARCTION USING TGF-ß ANTAGONISTS
WO2010093993A3 (en) Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
MX2021005992A (es) Gaboxadol para reducir el riesgo de suicidio y para alivio rápido de la depresión.
MX2011012310A (es) Tratamiento de insuficiencia cardiaca con fracción de eyeccion normal (icfen).
MX2022013236A (es) Tratamiento de la obesidad hipotalamica.
WO2011100659A3 (en) Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
WO2011009115A3 (en) Combination therapies for the treatment of obesity
MX2021013123A (es) Uso de co-cristales de tramadol y celecoxib para el tratamiento del dolor mientras se reduce la responsabilidad por abuso de tramadol.
Kim et al. A parametric study on the immunomodulatory effects of electroacupuncture in DNP-KLH immunized mice
WO2020097442A3 (en) Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases
MX2010003615A (es) Tratamiento de desordenes neurologicos.
MX2022002400A (es) Tratamiento de los sintomas inducidos por el ciclo menstrual.